BioXCell——助力体内临床前研究

BioXCell——助力体内临床前研究

BioXCell的中和/阻断抗体受到国内外研究者的普遍热爱和青睐,在肿瘤、癌症等方面的研究中广受好评。BioXCell公司位于美国新罕布什尔州,具有25年以上单克隆抗体和重组蛋白的生产及定制经验,可提供高纯度、低内毒素、无防腐剂、适用于体内临床前研究的单克隆抗体。

BioXCell——助力体内临床前研究 高纯度、低内毒素,无防腐剂,适用于体内临床前研究
超过二十五年单克隆抗体和重组蛋白生产及定制经验
性价比高,可提供100mg甚至50g的大包装
超过15000篇高质量期刊文献引用

肿瘤癌症免疫治疗应用 

抑制免疫检查点和其他免疫调节来治疗恶性肿瘤是现在利用免疫系统杀死肿瘤细胞的有力途径。BioXCell提供三种不同克隆号的anti mouse PD-1抗体:RMP1-14、29F.1A12和J43。三种抗体都通过相同的机制发挥作用—它们结合PD-1,并在空间上阻断PD-1与PD-1配体的结合,从而阻断PD-1信号传导。这三种克隆号的抗体都非常适合在小鼠体内模型中阻断PD-1信号传导,并有大量文献支持这一应用。这些抗体之间的差异在于文献报道中的其他应用、Isotype和来源。

通过用阻断PD-L1和它的受体PD-1之间的相互作用的抗体治疗,肿瘤生长可以暂时被抑制。

抗PD-1联合抗CTLA-4抗体介导的免疫治疗对黑色素瘤、肾细胞癌和非小细胞肺癌具有显著疗效。

通过靶向调节免疫反应的途径,如RANK途径,可以将“cold”肿瘤转化为“hot”肿瘤。使用Bio X Cell’s Anti-mouse RANKL (clone IK22/5) antibody,研究人员证明了对RANK通路的抑制将“cold”乳腺肿瘤转化为“hot”肿瘤,变为“hot”的肿瘤可能受益于免疫疗法。

肿瘤研究相关的抗体

抗体指标 应用 克隆号 InVivoMab InVivoPlus 同型对照 稀释液
Anti mouse PD-1(CD279) In vivo blocking of PD-1/PD-L signaling RMP1-14 BE0146 BP0146 BE0089 IP0070
In vivo blocking of PD-1/PD-L signaling
In vitro PD-1 neutralization
IHC-Fr/Immunofluorescence/WB/FC
29F.1A12 BE0273 BP0273 BE0089 IP0070
In vivo blocking of PD-1/PD-L signaling
In vitro PD-1 neutralization
WB
J43 BE0033-2 BP0033-2 BE0091 IP0065
Anti mouse PD-L1(B7-H1) In vivo PD-L1 blockade
IHC-Fr/Immunofluorescence/WB/FC
10F.9G2 BE0101 BP0101 BE0090 IP0065
Anti mouse CTLA-4 (CD152) In vivo CTLA-4 neutralization
WB
9D9 BE0164 BP0164 BE0086 IP0070
In vivo CTLA-4 neutralization
In vitro CTLA-4 neutralization
WB
9H10 BE0131 BP0131 BE0087 IP0070
In vivo CTLA-4 neutralization
In vitro CTLA-4 neutralization
WB/FC
UC10-4F10-11 BE0032 BP0032 BE0091 IP0065
Anti mouse CD4 In vivo CD4+ T cell depletion
WB/FC
GK1.5 BE0003-1 BP0003-1 BE0090 IP0065
Anti mouse CD8α In vivo CD8+ T cell depletion
Immunofluorescence/WB/FC
53-6.7 BE0004-1 BP0004-1 BE0089 IP0065
In vivo CD8+ T cell depletion
WB
2.43 BE0061 BP0061 BE0090 IP0070
In vivo CD8+ T cell depletion
WB
YTS 169.4 BE0117 BP0117 BE0090 IP0070
Anti mouse Ly6G In vivo neutrophil depletion
In vivo MDSC depletion
IHC-P/IHC-Fr/IF/FC
1A8 BE0075-1 BP0075-1 BE0089 IP0065
Anti mouse Ly6G/Ly6C (Gr-1) In vivo depletion of Gr-1+ myeloid cells
IHC-P/IHC-Fr/FC
RB6-8C5 BE0075 BP0075 BE0090 IP0070
Anti mouse IFNγ In vivo IFN-γ neutralization
In vitro IFN-γ neutralization
ELISPOT/WB/FC
XMG1.2 BE0055 BP0055 BE0088 IPT080
Anti mouse IFNAR-1 In vivo IFNAR-1 blockade
In vitro IFNAR-1 blockade
WB
MAR1-5A3 BE0241 BP0241 BE0083 IP0070

Anti-mouse/human/rat/monkey/hamster/

canine/bovine TGF-β

In vivo TGF-β neutralization
In vitro TGF-β neutralization
WB
1D11.16.8 BE0057 BP0057 BE0083 IP0070
Anti mouse CD28 In vitro T cell stimulation/activation
In vivo CD28 blockade
37.51 BE0015-1 / BE0087 IPT060
in vitro T cell stimulation/activation PV-1 BE0015-5 / BE0091 IP0070
Anti mouse CD3ε In vitro T cell stimulation/activation
In vivo T cell depletion
Immunofluorescence/WB/FC
145-2C11 BE0001-1 BP0001-1 BE0091 IP0070
Anti-human CD3 In vitro T cell stimulation/activation
In vivo T cell depletion in humanized mice
Ex vivo T cell inhibition for xenografts
FC
OKT-3 BE0001-2 / BE0085 IP0070
Anti mouse CD40 In vivo CD40 activation
In vitro B cell stimulation/activation
FGK4.5/ FGK45 BE0016-2 BP0016-2 BE0089 IP0070
Anti mouse CD154 (CD40L) In vivo blocking of CD40/CD40L signaling
In vitro blocking of CD40/CD40L signaling
WB
MR-1 BE0017-1 BP0017-1 BE0091 IP0070
Anti mouse CD25 (IL-2Rα) In vivo regulatory T cell depletion
FC
PC-61.5.3 BE0012 BP0012 BE0088 IP0070
Anti mouse IL-4 In vivo IL-4 neutralization
In vitro IL-4 neutralization
In vivo IL-4 receptor stimulation (as a complex with IL-4)
FC/WB
11B11 BE0045 BP0045 BE0088 IP0070
Anti mouse NK1.1 In vivo NK cell depletion
FC
PK136 BE0036 BP0036 BE0085 IP0070
Anti mouse CSF1R (CD115) In vivo macrophage depletion
In vitro CSF1R neutralization
In vivo monocyte depletion
FC/WB
AFS98 BE0213 BP0213 BE0089 IP0070
Anti mouse CD25 (IL-2Rα) In vivo regulatory T cell depletion
FC
PC-61.5.3 BE0012 BP0012 BE0088 IP0070
anti-mouse OX40 (CD134) In vivo OX40 activation
In vitro OX40 activation
WB
OX-86 BE0031 BP0031 BE0088 IP0070

畅销同型对照抗体

同型对照 InVivoMab InVivoPlus
目录号 目录号
Rat IgG2a Isotype control, FC BE0089 BP0089
Rat IgG2b Isotype control BE0090 BP0090
Mouse IgG1 Isotype control BE0083 BP0083
Rat IgG1 Isotype control BE0088 BP0088
Mouse IgG2a Isotype control BE0085 BP0085
Mouse IgG2b Isotype control BE0086 BP0086
Polyclonal Armenian Hamster IgG BE0091 BP0091

InVivoPlus™ Vs InVivoMab™系列之间区别

InVivoMab InVivoPlus
纯度 > 95% > 95%
蛋白完整性 √ (verified via SDS-PAGE) √ü(verified via SDS-PAGE)
内毒素浓度 < 2EU/mg < 1EU/mg
不含叠氮化物和载体蛋白
是否适用于体内研究
是否提供大包装
是否经WB, FC或ELISA验证
经验证蛋白聚集≤ 5%
是否经过鼠科病原体检测
产品货号 BE-开头 BP-开头

BioXCell的RecombiMAb系列抗体

BioXCell的RecombiMAb系列抗体是新开发的重组单克隆抗体,具有与其传统克隆号来源相同的抗原结合可变区,但IgG恒定区已从大鼠或仓鼠IgG变为小鼠或人IgG。这意味着对于小鼠模型或人源化小鼠模型的免疫原性降低。

RecombiMAb单克隆抗体

产品名称 宿主 亚型 货号 同型对照 稀释液 应用
Anti-Mouse PD-1 (CD279) (D265A) Mouse IgG2a, Κ CP151 CP150 IP0070 in vivo blocking of PD-1/PD-L signaling
Anti-Mouse CTLA-4 (CD152) Mouse IgG1, Κ CP146 BP0083 IP0070 In vivo CTLA-4 neutralization 
In vitro CTLA-4 neutralization 
WB
Human IgG4 (S228P) Isotype Control, Anti-Hen Egg Lysozyme Human IgG4, Κ CP147
Human IgG4 S228P L235E P329G (SPLEPG) Isotype Control, Anti-Hen Egg Lysozyme Human IgG4 CP148
Human IgG1 (LALA-PG) Isotype Control, Anti-Hen Egg Lysozyme Human IgG1 CP149
Mouse IgG2a (D265A) Isotype Control, Anti-Hen Egg Lysozyme Mouse IgG2a CP150

BioXCell的重组融合蛋白

融合蛋白即通过将细胞表面受体的结合域与抗体的Fc部分结合而形成,这样可以使得配体分子不会结合到内源性受体,从而阻断受体信号的传导。蛋白纯度大于95%,内毒素水平超低,不含防腐剂、稳定剂和载体蛋白等试剂,专为体内研究而开发。

货号 产品名称 货号 产品名称 规格
BE0099 InVivoMAb recombinant CTLA-4-lg BP0099 InVivoPlus recombinant CTLA-4-Ig 5mg,25mg,50mg,100mg
BE0098 InVivoMAb recombinant Flt-3L-lg BE0148 InVivoMAb recombinant Mouse Angiostatin-lg 5mg,25mg,50mg,100mg
BE0149 InVivoMAb recombinant Mouse Endostatin-lg 5mg,25mg,50mg,100mg


产品图片:

更多详情请咨询 Bioxcell代理商-上海金畔生物